The following information is disclosed in accordance with Rule 26 of the AIM Rules for Companies and was last updated on 17 July 2018. N4 Pharma Plc is incorporated in England (Registration Number 01435584). The Company’s principal country of operation is the United Kingdom.

AIM Securities Information

Number of AIM securities in issue – 101,462,537 (as at 20 February 2019) ordinary shares of 0.4p. No Ordinary Shares are held in treasury.

Significant Shareholders

Shareholder Number of Shares Held % of Issued Share Capital
Nigel Theobald 16,981,319 16.60%
David Farrier 11,675,366 11.51%
First Equity Limited 3,500,000 3.45%

Percentage of AIM securities not in public hands – 28.4% (as at 20 February 2019) 

The Company had previously included nominee account shareholdings in the table above and in the calculation for “shares not in public hands”. Having completed an analysis of the underlying beneficial shareholders to the nominee holdings, the Company has identified that there are no notifiable interests pursuant to AIM Rule 26 save for as included in the table above.


Nominated Adviser and Stockbroker

Allenby Capital
5 St Helen’s Place

Financial PR (Press and Analyst contact)

Alma PR
71-73 Carter Lane


Saffery Champness
71 Queen Victoria Street

Solicitors to the Company

Edwin Coe LLP
2 Stone Buildings
Lincolns Inn


Neville Registrars Limited
Neville House
18 Laurel Lane
West Midlands
B63 3DA

Corporate Governance and Director Responsibilities

It is the Board’s job to ensure that N4 Pharma Plc is managed for the long-term benefit of all shareholders, with effective and efficient decision-making. Corporate governance is an important part of that job, reducing risk and adding value to our business.

Read our Corporate Governance Statement of Compliance with the QCA Corporate Governance Code. This statement will be updated annually at the time of publication of the annual report and accounts. The statement was last updated on 04 July 2019.